tadalafil + placebo

Phase 2Withdrawn

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sickle Cell Anemia

Conditions

Sickle Cell Anemia, Priapism

Trial Timeline

Nov 1, 2006 → Aug 1, 2009

NCT ID

NCT00538564

About tadalafil + placebo

tadalafil + placebo is a phase 2 stage product being developed by Eli Lilly for Sickle Cell Anemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00538564. Target conditions include Sickle Cell Anemia, Priapism.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01865084	Phase 3	Terminated	Sep 1, 2013	Mar 1, 2016	Muscular Dystrophy, Duchenne
NCT01460342	Phase 3	Completed	Dec 1, 2011	Oct 1, 2012	Benign Prostatic Hyperplasia
NCT01152190	Phase 3	Completed	Sep 1, 2010	Jul 1, 2012	Benign Prostatic Hyperplasia
NCT01130532	Approved	Completed	Aug 1, 2010	Jan 1, 2012	Erectile Dysfunction
NCT01026818	Approved	Completed	Nov 1, 2009	Oct 1, 2012	Erectile Dysfunction
NCT00848081	Phase 3	Completed	Mar 1, 2009	Dec 1, 2009	Benign Prostatic Hyperplasia
NCT00855582	Phase 3	Completed	Mar 1, 2009	Jul 1, 2010	Erectile Dysfunction
NCT00836693	Phase 3	Completed	Jan 1, 2009	Jan 1, 2010	Erectile Dysfunction
NCT00422734	Phase 3	Completed	Nov 1, 2006	Jan 1, 2008	Impotence
NCT00538564	Phase 2	Withdrawn	Nov 1, 2006	Aug 1, 2009	Sickle Cell Anemia
NCT00386009	Phase 2	Completed	Oct 1, 2006	May 1, 2008	Benign Prostatic Hyperplasia
NCT00547625	Phase 2	Completed	Oct 1, 2004	Jul 1, 2005	Prostatic Hyperplasia
NCT00382135	Approved	Completed	Nov 1, 2003	Dec 1, 2005	Erectile Dysfunction
NCT00381732	Phase 3	Completed	Oct 1, 2003	Jun 1, 2006	Erectile Dysfunction

Competing Products

20 competing products in Sickle Cell Anemia

See all competitors

Product	Company	Stage	Hype Score
Prasugrel + Placebo	Daiichi Sankyo	Phase 3	77
Prasugrel	Daiichi Sankyo	Phase 1	33
Prasugrel + Placebo	Daiichi Sankyo	Phase 2	52
Prasugrel	Daiichi Sankyo	Phase 2	52
Lexiscan	Astellas Pharma	Phase 1	33
Placebo + Dalteparin	Eisai	Phase 2	52
Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT])	Eli Lilly	Phase 1	33
Lidocaine Iv + Placebo	Johnson & Johnson	Phase 2	52
ICA-17043	Johnson & Johnson	Phase 3	77
Ticagrelor	AstraZeneca	Phase 1	33
Ticagrelor granule + Ticagrelor pediatric tablets + Ticagrelor pediatric tablets suspended in water + Ticagrelor immediate release (IR) tablets (Commercial tablet)	AstraZeneca	Phase 1	33
Ticagrelor + Placebo	AstraZeneca	Phase 2	52
Ticagrelor + Placebo	AstraZeneca	Phase 3	77
Brilinta + Placebo	AstraZeneca	Phase 3	77
Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b	AstraZeneca	Phase 2	52
vorinostat	Merck	Phase 2	52
Crizanlizumab + Placebo	Novartis	Phase 3	77
Crizanlizuamb + Standard of Care	Novartis	Phase 2	52
Crizanlizumab	Novartis	Approved	85
Hydroxyurea	Novartis	Phase 3	77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved